TherapeuticsMD, Inc. (NASDAQ: TXMD) Stock Competitors & Peer Comparison
See TXMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TXMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXMD | $1.74 | +1.75% | 19.7M | 86.60 | $0.02 | N/A |
| TAK | $21.02 | -0.80% | 65.8B | 15.11 | $1.39 | +3.36% |
| TEVA | $42.61 | +1.99% | 49.6B | 14.54 | $2.93 | N/A |
| HLN | $9.14 | -0.11% | 40.2B | 18.69 | $0.49 | +2.18% |
| ZTS | $79.40 | -3.30% | 32.8B | 12.07 | $6.58 | +2.66% |
| VTRS | $19.91 | +4.96% | 22.9B | 7.90 | $2.52 | +2.44% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $25.74 | +8.70% | 12.8B | 24.26 | $1.06 | N/A |
| RDY | $14.91 | +2.62% | 12.4B | 31.71 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
TXMD vs TAK Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TAK has a market cap of 65.8B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TAK trades at $21.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TAK's P/E ratio is 15.11. In terms of profitability, TXMD's ROE is -0.01%, compared to TAK's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
TXMD vs TEVA Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TEVA has a market cap of 49.6B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TEVA trades at $42.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TEVA's P/E ratio is 14.54. In terms of profitability, TXMD's ROE is -0.01%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TEVA's competition here
Haleon plc (NYSE: HLN)
TXMD vs HLN Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, HLN has a market cap of 40.2B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while HLN trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas HLN's P/E ratio is 18.69. In terms of profitability, TXMD's ROE is -0.01%, compared to HLN's ROE of +0.10%. Regarding short-term risk, TXMD is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
TXMD vs ZTS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ZTS trades at $79.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ZTS's P/E ratio is 12.07. In terms of profitability, TXMD's ROE is -0.01%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, TXMD is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
TXMD vs VTRS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, VTRS has a market cap of 22.9B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while VTRS trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas VTRS's P/E ratio is 7.90. In terms of profitability, TXMD's ROE is -0.01%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, TXMD is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TXMD vs ITCI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TXMD's ROE is -0.01%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TXMD vs ELAN Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ELAN has a market cap of 12.8B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ELAN trades at $25.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ELAN's P/E ratio is 24.26. In terms of profitability, TXMD's ROE is -0.01%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, TXMD is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TXMD vs RDY Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while RDY trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas RDY's P/E ratio is 31.71. In terms of profitability, TXMD's ROE is -0.01%, compared to RDY's ROE of +0.07%. Regarding short-term risk, TXMD is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
TXMD vs CTLT Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TXMD's ROE is -0.01%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TXMD is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
TXMD vs ALKS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ALKS trades at $45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ALKS's P/E ratio is 48.34. In terms of profitability, TXMD's ROE is -0.01%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, TXMD is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TXMD vs AMRX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AMRX has a market cap of 7B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AMRX trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AMRX's P/E ratio is 22.37. In terms of profitability, TXMD's ROE is -0.01%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, TXMD is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TXMD vs LNTH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while LNTH trades at $100.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas LNTH's P/E ratio is 16.91. In terms of profitability, TXMD's ROE is -0.01%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, TXMD is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TXMD vs INDV Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas INDV's P/E ratio is 9.94. In terms of profitability, TXMD's ROE is -0.01%, compared to INDV's ROE of -3.53%. Regarding short-term risk, TXMD is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TXMD vs BHC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while BHC trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas BHC's P/E ratio is 2.09. In terms of profitability, TXMD's ROE is -0.01%, compared to BHC's ROE of +0.59%. Regarding short-term risk, TXMD is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TXMD vs HCM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while HCM trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas HCM's P/E ratio is 147.29. In terms of profitability, TXMD's ROE is -0.01%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HCM's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TXMD vs RGC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while RGC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas RGC's P/E ratio is -531.50. In terms of profitability, TXMD's ROE is -0.01%, compared to RGC's ROE of -1.61%. Regarding short-term risk, TXMD is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RGC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TXMD vs DCPH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TXMD's ROE is -0.01%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TXMD is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DCPH's competition here
Perrigo Company plc (NYSE: PRGO)
TXMD vs PRGO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PRGO trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PRGO's P/E ratio is 6.34. In terms of profitability, TXMD's ROE is -0.01%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, TXMD is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PRGO's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TXMD vs AVDL Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TXMD's ROE is -0.01%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, TXMD is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
TXMD vs TRLV Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TRLV trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TRLV's P/E ratio is -4.69. In terms of profitability, TXMD's ROE is -0.01%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, TXMD is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
TXMD vs EMBCV Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.01%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TXMD is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TXMD vs DVAX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TXMD's ROE is -0.01%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, TXMD is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
TXMD vs ALVO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ALVO trades at $4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ALVO's P/E ratio is -8.15. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TXMD is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALVO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TXMD vs TARO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TARO's P/E ratio is 30.05. In terms of profitability, TXMD's ROE is -0.01%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TARO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TXMD vs ETON Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ETON trades at $56.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ETON's P/E ratio is 148.58. In terms of profitability, TXMD's ROE is -0.01%, compared to ETON's ROE of +1.05%. Regarding short-term risk, TXMD is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TXMD vs ANIP Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ANIP has a market cap of 1.5B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ANIP trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ANIP's P/E ratio is 8.20. In terms of profitability, TXMD's ROE is -0.01%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, TXMD is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ANIP's competition here
Supernus, Inc. (NASDAQ: SUPN)
TXMD vs SUPN Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SUPN has a market cap of 1.5B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SUPN trades at $26.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SUPN's P/E ratio is -34.55. In terms of profitability, TXMD's ROE is -0.01%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, TXMD is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SUPN's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TXMD vs PCRX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PCRX trades at $36.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PCRX's P/E ratio is 14.01. In terms of profitability, TXMD's ROE is -0.01%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TXMD vs PAHC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PAHC trades at $32.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PAHC's P/E ratio is 11.25. In terms of profitability, TXMD's ROE is -0.01%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, TXMD is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
TXMD vs CRON Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CRON trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CRON's P/E ratio is 18.51. In terms of profitability, TXMD's ROE is -0.01%, compared to CRON's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CRON's competition here
Alvotech (NASDAQ: ALVOW)
TXMD vs ALVOW Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ALVOW has a market cap of 1.3B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ALVOW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ALVOW's P/E ratio is 20.44. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TXMD is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALVOW's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TXMD vs AMPH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AMPH trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AMPH's P/E ratio is 9.72. In terms of profitability, TXMD's ROE is -0.01%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, TXMD is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TXMD vs HROW Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while HROW trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas HROW's P/E ratio is -27.19. In terms of profitability, TXMD's ROE is -0.01%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TXMD is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TXMD vs PETQ Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TXMD's ROE is -0.01%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TXMD vs COLL Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, COLL has a market cap of 787.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while COLL trades at $24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas COLL's P/E ratio is 3.04. In terms of profitability, TXMD's ROE is -0.01%, compared to COLL's ROE of +0.12%. Regarding short-term risk, TXMD is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TXMD vs IRWD Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, IRWD has a market cap of 725.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while IRWD trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas IRWD's P/E ratio is 5.63. In terms of profitability, TXMD's ROE is -0.01%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, TXMD is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
TXMD vs EVO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas EVO's P/E ratio is -2.39. In terms of profitability, TXMD's ROE is -0.01%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TXMD is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TXMD vs BDSI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TXMD's ROE is -0.01%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TXMD is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TXMD vs TKNO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TKNO has a market cap of 481.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TKNO trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TKNO's P/E ratio is -25.19. In terms of profitability, TXMD's ROE is -0.01%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TXMD is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
TXMD vs EOLS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, EOLS has a market cap of 452.8M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while EOLS trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas EOLS's P/E ratio is -21.71. In terms of profitability, TXMD's ROE is -0.01%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, TXMD is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TXMD vs AQST Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AQST has a market cap of 452.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AQST trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AQST's P/E ratio is -5.54. In terms of profitability, TXMD's ROE is -0.01%, compared to AQST's ROE of +2.55%. Regarding short-term risk, TXMD is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
TXMD vs KMDA Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, KMDA has a market cap of 416.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while KMDA trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas KMDA's P/E ratio is 19.00. In terms of profitability, TXMD's ROE is -0.01%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TXMD is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check KMDA's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TXMD vs ACB Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ACB has a market cap of 331.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ACB trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ACB's P/E ratio is -3.78. In terms of profitability, TXMD's ROE is -0.01%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TXMD is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ACB's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TXMD vs TLRY Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TLRY has a market cap of 326.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TLRY trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TLRY's P/E ratio is -2.09. In terms of profitability, TXMD's ROE is -0.01%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
TXMD vs EBS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, EBS has a market cap of 309.7M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while EBS trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas EBS's P/E ratio is 4.19. In terms of profitability, TXMD's ROE is -0.01%, compared to EBS's ROE of -0.61%. Regarding short-term risk, TXMD is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TXMD vs ALIM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is -0.01%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TXMD is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALIM's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TXMD vs CGC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CGC has a market cap of 275.8M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CGC trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CGC's P/E ratio is -1.46. In terms of profitability, TXMD's ROE is -0.01%, compared to CGC's ROE of -0.37%. Regarding short-term risk, TXMD is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CGC's competition here
Landec Corporation (NASDAQ: LNDC)
TXMD vs LNDC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, TXMD is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LNDC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TXMD vs LFCR Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, LFCR has a market cap of 241.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while LFCR trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas LFCR's P/E ratio is -5.01. In terms of profitability, TXMD's ROE is -0.01%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, TXMD is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
TXMD vs TYHT Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TXMD's ROE is -0.01%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TXMD is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TXMD vs SIGA Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SIGA has a market cap of 223.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SIGA trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SIGA's P/E ratio is 11.52. In terms of profitability, TXMD's ROE is -0.01%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TXMD is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
TXMD vs GLAS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, GLAS has a market cap of 182.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while GLAS trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas GLAS's P/E ratio is -3.71. In terms of profitability, TXMD's ROE is -0.01%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TXMD is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TXMD vs REPH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas REPH's P/E ratio is -8.04. In terms of profitability, TXMD's ROE is -0.01%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TXMD vs THTX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas THTX's P/E ratio is -28.83. In terms of profitability, TXMD's ROE is -0.01%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TXMD is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TXMD vs ASRT Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TXMD's ROE is -0.01%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TXMD is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
TXMD vs DERM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, DERM has a market cap of 126.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while DERM trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas DERM's P/E ratio is -20.36. In terms of profitability, TXMD's ROE is -0.01%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TXMD is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
TXMD vs OGI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, OGI has a market cap of 123.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while OGI trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas OGI's P/E ratio is 1.97. In terms of profitability, TXMD's ROE is -0.01%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TXMD is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TXMD vs CRDL Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CRDL has a market cap of 119.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CRDL trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CRDL's P/E ratio is -3.94. In terms of profitability, TXMD's ROE is -0.01%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TXMD is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CRDL's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TXMD vs SCTL Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TXMD's ROE is -0.01%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
TXMD vs BGM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, BGM has a market cap of 111.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while BGM trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas BGM's P/E ratio is -1.83. In terms of profitability, TXMD's ROE is -0.01%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TXMD is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check BGM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TXMD vs ORGO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ORGO has a market cap of 104.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ORGO trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ORGO's P/E ratio is 27.11. In terms of profitability, TXMD's ROE is -0.01%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, TXMD is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ORGO's competition here
Procaps Group S.A. (NASDAQ: PROC)
TXMD vs PROC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PROC's P/E ratio is 1.53. In terms of profitability, TXMD's ROE is -0.01%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TXMD vs OPTN Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TXMD is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TXMD vs ZOM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TXMD's ROE is -0.01%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, TXMD is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
TXMD vs GRVI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TXMD's ROE is -0.01%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, TXMD is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check GRVI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TXMD vs CPIX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CPIX has a market cap of 78.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CPIX trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CPIX's P/E ratio is -13.02. In terms of profitability, TXMD's ROE is -0.01%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TXMD is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CPIX's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TXMD vs ZYBT Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ZYBT trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, TXMD is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TXMD vs ZYNE Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TXMD is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TXMD vs SSIC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TXMD's ROE is -0.01%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TXMD is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TXMD vs VLNS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TXMD's ROE is -0.01%, compared to VLNS's ROE of N/A. Regarding short-term risk, TXMD is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
TXMD vs DRRX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TXMD's ROE is -0.01%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, TXMD is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
TXMD vs TLPH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, TLPH has a market cap of 55M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas TLPH's P/E ratio is -3.93. In terms of profitability, TXMD's ROE is -0.01%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TXMD is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TLPH's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TXMD vs JUPW Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TXMD's ROE is -0.01%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TXMD is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check JUPW's competition here
InterCure Ltd. (NASDAQ: INCR)
TXMD vs INCR Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, INCR has a market cap of 39.7M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while INCR trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas INCR's P/E ratio is -3.53. In terms of profitability, TXMD's ROE is -0.01%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INCR's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TXMD vs QLI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas QLI's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is -0.01%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TXMD is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TXMD vs RMTI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, RMTI has a market cap of 31.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while RMTI trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas RMTI's P/E ratio is -5.79. In terms of profitability, TXMD's ROE is -0.01%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TXMD is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
TXMD vs HEXO Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TXMD's ROE is -0.01%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TXMD is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HEXO's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TXMD vs SHPH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SHPH has a market cap of 25.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SHPH trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SHPH's P/E ratio is -0.25. In terms of profitability, TXMD's ROE is -0.01%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TXMD is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SHPH's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TXMD vs CPHI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CPHI has a market cap of 24.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CPHI trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CPHI's P/E ratio is -1.31. In terms of profitability, TXMD's ROE is -0.01%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TXMD is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TXMD vs CYTH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TXMD's ROE is -0.01%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TXMD is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TXMD vs AYTU Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AYTU has a market cap of 19.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AYTU trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AYTU's P/E ratio is -1.52. In terms of profitability, TXMD's ROE is -0.01%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TXMD is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TXMD vs EVOK Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TXMD's ROE is -0.01%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, TXMD is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TXMD vs ACRX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TXMD's ROE is -0.01%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TXMD is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TXMD vs OPTH Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, OPTH has a market cap of 12.9M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while OPTH trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas OPTH's P/E ratio is -1.45. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TXMD is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TXMD vs AGRX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TXMD's ROE is -0.01%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TXMD is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
TXMD vs CABR Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, CABR has a market cap of 9.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while CABR trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas CABR's P/E ratio is -1.32. In terms of profitability, TXMD's ROE is -0.01%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TXMD is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CABR's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TXMD vs NLTX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TXMD's ROE is -0.01%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TXMD is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
TXMD vs INM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, INM has a market cap of 8.1M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas INM's P/E ratio is -4.80. In terms of profitability, TXMD's ROE is -0.01%, compared to INM's ROE of -2.64%. Regarding short-term risk, TXMD is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
TXMD vs LCI Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas LCI's P/E ratio is -0.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TXMD is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TXMD vs ADMP Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TXMD's ROE is -0.01%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TXMD is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ADMP's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
TXMD vs SBFM Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SBFM trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SBFM's P/E ratio is -0.45. In terms of profitability, TXMD's ROE is -0.01%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, TXMD is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SBFM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TXMD vs SNOA Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SNOA has a market cap of 5.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SNOA trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SNOA's P/E ratio is -1.00. In terms of profitability, TXMD's ROE is -0.01%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TXMD is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
TXMD vs MNK Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas MNK's P/E ratio is -0.44. In terms of profitability, TXMD's ROE is -0.01%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
TXMD vs YCBD Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, YCBD has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while YCBD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas YCBD's P/E ratio is -0.99. In terms of profitability, TXMD's ROE is -0.01%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TXMD is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TXMD vs FLGC Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TXMD's ROE is -0.01%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TXMD is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
TXMD vs SBFMW Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas SBFMW's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.01%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, TXMD is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TXMD vs GELS Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, GELS has a market cap of 4M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while GELS trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas GELS's P/E ratio is -1.00. In terms of profitability, TXMD's ROE is -0.01%, compared to GELS's ROE of -0.36%. Regarding short-term risk, TXMD is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TXMD vs PLXP Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TXMD's ROE is -0.01%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TXMD is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
TXMD vs ATNX Comparison November 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 19.7M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TXMD is priced at $1.74 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 86.60, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TXMD's ROE is -0.01%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TXMD is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ATNX's competition here